Cogent Biosciences, Inc. — 2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021; filed March 15, 2022. This is an annual filing, not a standalone fourth-quarter report.
Business context
Cogent is a clinical-stage biotechnology company developing precision therapies for genetically defined diseases. Its lead candidate, bezuclastinib (CGT9486), is designed to inhibit mutant KIT, including KIT D816V. The company had no approved products and generated no product sales revenue.
In 2021, Cogent began three bezuclastinib trials: APEX, a Phase 2 study in advanced systemic mastocytosis (AdvSM); SUMMIT, a Phase 2 study in non-advanced systemic mastocytosis; and PEAK, a Phase 3 study combining bezuclastinib with sunitinib for previously treated GIST. All were recruiting at year-end. The company also formed a Boulder-based research team to develop additional small-molecule programs.
Key financial metrics
| Metric | 2021 | 2020 |
|---|---|---|
| Revenue | $0 | $7.9 million collaboration revenue |
| Research and development expense | $55.9 million | $25.7 million |
| General and administrative expense | $19.6 million | $17.4 million |
| Operating loss | $75.6 million | $82.2 million |
| Net loss | $72.3 million | $74.8 million |
| Net loss per share, basic and diluted | $1.87 | $16.17 |
| Cash used in operating activities | $58.8 million | $35.9 million |
| Cash and cash equivalents at year-end | $219.7 million | $242.2 million |
Margins are not meaningful because the company had no product sales. Total assets were $232.1 million and total liabilities were $17.9 million at December 31, 2021. The filing reports no debt; liabilities primarily included leases and the contingent value right (CVR). Current assets of $222.6 million exceeded current liabilities of $17.1 million. Restricted cash of $1.3 million was reported separately from cash and cash equivalents.
Changes versus 2020
- R&D expense rose $30.2 million, reflecting bezuclastinib development and manufacturing, pipeline research, and increased headcount. G&A expense rose $2.2 million, primarily from personnel costs.
- Operating cash use increased $22.9 million, while cash balances declined $22.5 million. The company raised $38.0 million net through its at-the-market (ATM) stock offering in 2021, compared with $232.2 million of financing cash inflows in 2020.
- 2020 included $7.9 million of collaboration revenue, a $46.9 million acquired in-process R&D charge for the Kiq acquisition, and a $7.5 million gain on asset disposals; none of these items recurred in 2021. The 2020 common-stockholder loss and loss per share also included a $104.4 million deemed preferred-stock dividend, affecting comparison with 2021.
Outlook, risks and unusual items
- Management estimated that year-end cash and cash equivalents would fund operating expenses and capital requirements into 2024, based on current plans and assumptions. It expects continued losses and substantial additional funding needs; actual cash needs may exceed estimates.
- Management expected preliminary APEX data in the first half of 2022. This is a forward-looking statement made in the 2021 filing, not an update on subsequent results.
- In an earlier Phase 1/2 GIST trial, the combination of bezuclastinib and sunitinib produced a 20% confirmed response rate and estimated median progression-free survival of 12 months among 15 heavily pretreated patients without prior single-agent bezuclastinib. The small sample limits how broadly these results can be generalized.
- Bezuclastinib’s active pharmaceutical ingredient and drug product relied on single-source third-party suppliers; the company had no long-term supply agreements or validated commercial manufacturing process. Manufacturing interruptions could delay trials or future commercialization.
- The Plexxikon license provides for up to $7.5 million in clinical milestones, up to $25.0 million in regulatory milestones, and tiered royalties. The filing said $2.5 million of clinical milestones could become payable in the following 12 months as trials progressed.
- Cogent reported a $3.1 million CVR liability at year-end. Major risks include clinical and regulatory failure, competition, patient-enrollment delays, COVID-19 disruption, reliance on external suppliers, intellectual-property challenges, and the need for additional financing and potential shareholder dilution.
- The company entered a 12-year Boulder lease, with rent expected to begin in 2022 and an estimated $8–$10 million facility build-out; the landlord was expected to contribute approximately $6.9 million toward improvements and could provide a tenant-improvement loan.
Important facts for investors to verify
- Current clinical-trial status, enrollment, safety findings, and reported results for APEX, SUMMIT, and PEAK, including whether the filing’s 2022 milestones were achieved.
- Cash runway against actual quarterly cash burn, planned trial costs, Boulder build-out spending, and the company’s stated need for additional financing.
- Potential dilution from the outstanding Series A preferred stock, which was convertible into approximately 25.8 million common shares at year-end 2021, as well as equity compensation and any later securities issuance.
- Progress in qualifying alternative suppliers and establishing scalable, compliant manufacturing for bezuclastinib.
- Milestone and royalty obligations under the Plexxikon license, the remaining CVR obligation, and any subsequent changes to these commitments.